Comments on: Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

Comments on: Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC https://9krapalm.com/abbisko-therapeutics-and-astrazeneca-enter-a-strategic-collaboration-to-conduct-the-clinical-trial-of-lumipodlin-absk043-a-first-in-class-oral-pd-l1-inhibitor-in-combination-with-tagrisso-fo/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Thu, 02 Jul 2026 02:07:01 +0000 hourly 1 https://wordpress.org/?v=7.0